INTRODUCTION
Tourette's syndrome (TS) is a chronic, childhood-onset neuropsychiatric disorder characterized by multiple motor tics and at least one phonic tic that persist for 41 year. 1, 2 TS has a population prevalence of B0.3--0.8% and, like many neurodevelopmental disorders, occurs more frequently in boys, with male/female ratios ranging between 3:1 and 4:1. 3, 4 It is frequently accompanied by a wide range of additional psychiatric comorbidities, in particular obsessive--compulsive disorder (OCD) and attention-deficit hyperactivity disorder. 5 TS causes substantial physical and psychosocial morbidity in children and adolescents, and can produce lifelong disability in severe cases. 6, 7 Twin and family studies have repeatedly demonstrated that TS is highly heritable. 8 First-degree relatives of affected individuals have a 5-to 15-fold increased risk of TS compared with that of the general population, representing one of the highest familial recurrence risks among common neuropsychiatric diseases. 3, 9 However, despite this strong familiality, identification of TS susceptibility genes has been challenging. Linkage analyses have produced inconsistent results, although a recent study combining multigenerational families with affected sibling pairs has identified at least one major TS locus on chromosome 2p. 10 Multiple candidate genes have also been proposed, although none have been consistently replicated. 8 Mutations in the strongest TS candidate genes (SLITRK1, CNTNAP2 and HDC) have been found only in single families or a small number of individuals, suggesting that, if truly causative, they account for only a small proportion of TS cases. 11--15 Thus, additional gene-finding strategies are needed. Here, we report the first TS genome-wide association study (GWAS) in a large cohort of samples of general European ancestry, as well as two European-derived population isolates, Ashkenazi Jews from the United States and Israel (AJ) and French Canadians from Quebec, Canada (FC), and two closely related Latin American population isolates, the Central Valley of Costa Rica (CVCR) and Antioquia, Colombia (ANT).
MATERIALS AND METHODS Cases
A total of 1998 TS cases were recruited from 20 sites in the United States, Canada, UK, The Netherlands, Israel, Costa Rica and Colombia and divided into four strata based on self-reported ancestry: (1) 1252 European ancestry, nonisolate cases from North America and Europe (EU); (2) 210 Ashkenazi Jewish cases from the United States and Israel (AJ); (3) 302 French Canadian cases (FC); and (4) cases from two closely related population isolates from the Central Valley of Costa Rica (CVCR; n ¼ 137) and Antioquia, Colombia (ANT; n ¼ 97) (see Supplementary Methods). Inclusion criteria required a TS Classification Study Group (TSCSG) diagnosis of definite TS (a DSM-IV-TR diagnosis of TS plus tics observed by an experienced clinician), 16 and available genomic DNA extracted either from blood or cell lines. Exclusion criteria consisted of a history of intellectual disability, tardive tourettism or other known genetic, metabolic or acquired tic disorders. Subjects from 17 of the 20 sites were assessed for a lifetime diagnosis of TS, OCD and attention-deficit hyperactivity disorder using a standardized and validated semistructured interview that has high validity and reliability for TS (k ¼ 1.00) and OCD (k ¼ 0.97). 10 Subjects from the other three sites were assessed only for a lifetime diagnosis of definite TS.
Controls
A total of 5403 European ancestry controls were derived primarily from cohorts of previously genotyped, unselected population controls (see Supplementary Methods, Supplementary Table S1 ). These included 3212 controls from the Illumina Genotype Control Database genotyped on the Illumina HumanHap550v1/v3 platforms (www.Illumina.com, Illumina, San Diego, CA, USA), 1288 controls from the Studies of Addiction: Genetics and Environment (SAGE) cohort 17--19 genotyped on the Illumina Human-Hap1Mv1_C and 653 Dutch ancestry controls genotyped on the Illumina HumanHap550v1. 20 An additional 298 German and Dutch EU controls were genotyped simultaneously with the TS case samples, including 48 duplicates from the Dutch 550v1 control cohort, to facilitate cross-platform and cross-facility comparisons.
A total of 297 FC and 380 ANT ancestry-matched controls were collected in parallel with their respective cases (see Supplementary Methods). ANT controls were used for analysis of both ANT and CVCR cases given their shared ancestry. 21, 22 All participants X18 years of age gave informed consent. Individuals o18 years of age gave assent after a parent signed a consent form on their behalf. The research project was approved by the ethics committees of each participating site.
Genotyping
Genotyping of 908 of the 1252 EU cases and all population-isolate cases (AJ, FC, ANT and CVCR), as well as 298 EU and all FC and ANT controls, was conducted on the Illumina Human610-Quadv1_B SNP array (Illumina) at the Broad Institute of Harvard and MIT (Cambridge, MA, USA) in two batches using standard protocols. Samples were randomized across plates and batches both by originating site and case--control status. Genotype calling was performed using BeadStudio (Illumina). In addition, 432 EU cases were genotyped on the Illumina HumanCNV370-Duo_v1 at the Yale Center for Genome Analysis (New Haven, CT, USA), including 88 duplicate EU samples overlapping with those genotyped on the 610-Quad platform to allow for cross-platform checks of concordance.
Quality control
Quality control (QC) analyses were performed using PLINK v1.07 (ref. 23) and EIGENSTRAT. 24 In addition to standard QC protocols, particular detail focused on cross-platform comparisons of concordance, allele frequency and differential missingness, given the use of control samples genotyped previously on different Illumina platforms (full details and ordered QC pipeline available online, Supplementary Figure S1 ). In general, two thresholds were used for single-nucleotide polymorphism (SNP) QC: a more stringent threshold at which SNPs were removed, and a second liberalized threshold for which SNPs were flagged and re-examined later for potential QC-related bias. All flagged SNPs with Po1 Â 10 À3 in any analysis are annotated in Supplementary Tables S2--S4. Sample and SNP QC were initially performed within each platform separately (Supplementary Figure S1 ). Samples were removed for autosomal call rates o98%, discrepancy between phenotypic and genetic sex, and indeterminate genetic sex. In addition, all 151 cases from one site were removed because of increased rates of missing SNP data relative to other sites (Supplementary Figure S2 ). Platform-specific SNP QC included removing monomorphic SNPs, copy number variation targeted SNP probes, SNPs with genotyping rate o98% and strand-ambiguous SNPs with significant allele frequency differences or aberrant linkage disequilibrium (LD) correlations with adjacent SNPs based on the entire HapMap2 reference panel. Concordance was checked between 82 duplicates genotyped both on the 610-Quad (Broad) and 370K (Yale), as well as 41 duplicates genotyped on the 610-Quad and 550v1. In addition, concordance was examined in HapMap duplicates from the Illumina database genotyped on two or more platforms used in this study. No SNPs were identified with significant association between the two 610-Quad genotyping batches.
After merging samples from all platforms, SNPs with minor allele frequency difference of 40.15 between case--case or control--control platforms were flagged, as were SNPs with 41% Mendelian errors in a parallel sample of 400 OCD trios genotyped simultaneously with the TS cases. 25 Any SNP not present on the three major common platforms (550v1, 610-Quad and 1M) was removed, leaving 496 877 SNPs for population-specific QC.
Multidimensional scaling analysis was used to exclude duplicate and related samples as well as samples of non-European descent (other than the CVCR/ANT samples, which were set aside for subpopulation-specific QC; Supplementary Figure S3 ). Remaining EU and European-derived isolate samples were separated into three strata (EU, AJ and FC) based on observed genetic ancestry and source population ( Supplementary Figures S4--S6 ). Within each of the multidimensional scaling-defined genetic subpopulations, additional outliers were removed for excess low-level relatedness, abnormal average heterozygosity or inadequate case--control matching. The final European ancestry sample contained 1285 cases and 4964 controls (EU: 778 cases and 4414 controls; AJ: 242 cases and 354 controls; FC: 265 cases and 196 controls; see Table 1 and Supplementary Figure S1 ). The final CVCR/ANT sample consisted of 211 cases (87 ANT, 124 CVCR) and 285 ANT controls.
Subpopulation-specific SNP QC included removal of SNPs with Hardy--Weinberg equilibrium Po10 À10 in controls (flagged for Hardy--Weinberg equilibrium Po10 À5 ) and two additional cross-platform QC steps to remove SNPs with differential missingness between cases and controls across the five Illumina data sets (Supplementary Figure S7 ). The final number of SNPs for meta-analyses across all populations was 484 295 SNPs.
Genetic association and meta-analysis
Four ancestry-stratified association analyses were performed using PLINK, version 1.07, (ref. 23) employing logistic regression under an additive model with significant subpopulation-specific multidimensional scaling dimensions included as covariates to control for residual population stratification. Strata were then combined in a case-weighted meta-analysis in METAL, 26 assuming a fixed-effects model. For X-chromosome SNPs, males and females were analyzed separately first and subsequently combined by meta-analysis (Supplementary Methods). For all SNPs, two meta-analyses were conducted: a primary analysis with the Europeanderived strata only (EU, AJ and FC), and an exploratory, secondary metaanalysis including the CVCR/ANT Latin American samples. Heterogeneity was assessed using Cochran's Q and I 2 statistics.
Enrichment analyses
Expression quantitative trait loci (eQTL) data from lymphoblast cell lines (LCLs), cerebellum and frontal cortex were generated as described previously. 27--29 Similarly, methylation QTLs (mQTLs), which represent SNPs that are associated with variation in genome-wide patterns of methylation, were derived from adult cerebellum. 30 The top distribution of GWAS SNPs from the primary meta-analysis, 412 LD-pruned SNPs with Po0.001, were tested for eQTL or mQTL enrichment compared with 1000 randomly drawn, LD-pruned sets of allele frequency-matched SNPs taken from the set of typed SNPs on the Illumina 550K (Supplementary Methods). The number of eQTLs (or mQTLs) in each simulated set yielded an empirical distribution and enrichment P-value, calculated as the proportion of randomized sets in which the eQTL/mQTL count matched or exceeded the actual observed count in the list of top SNP associations. A similar analysis was performed to test for enrichment of missense SNPs or SNPs within a gene as defined by dbSNP annotation. Imputation Imputation of SNPs from the 1000 Genomes Project was performed using IMPUTE2 (ref. 31 ) and haplotypes from all 1092 individuals in the 1000 Genomes June 2011 Data Release 32 as a reference data set (Supplementary Methods). Postimputation QC and allelic dosage analysis were conducted in each subpopulation separately in PLINK followed by case-weighted meta-analysis in METAL.
RESULTS

QC analyses in individual ancestral subpopulations
After QC filtering, 1285 cases and 4964 controls remained across the three European ancestry strata (EU, AJ and FC). Examination of quantile-quantile (Q-Q) plots and genomic control l values of the individual subpopulation-specific analyses revealed no evidence of residual population stratification or systematic technical artifact (EU, l ¼ 1.011; AJ, l ¼ 0.993; FC, l ¼ 0.971; Supplementary Figure S8a --c). The Latin American population isolate stratum (CVCR/ANT) showed a small inflation of the median test statistic (l ¼ 1.044), indicative of some residual stratification between CVCR and ANT samples (Supplementary Figure S6 ). However, no SNPs in this subpopulation-specific analysis had extreme P-values outside the expected null distribution (Supplementary Figure S8d ).
Primary meta-analysis of GWAS data from European-derived subpopulations In the primary meta-analysis of European-derived samples, no SNP surpassed a genome-wide significant threshold of Po5.0 Â 10 À8 (Figure 1 ). The top five LD-independent loci are annotated in Table 2 ; full annotation of all SNPs with Po1 Â 10 À3 are provided in Supplementary Table S2 . The SNP with the strongest signal, rs7868992, lies on chromosome 9q32 within an intron of COL27A1 (P ¼ 1.85 Â 10 À6 ; Supplementary Figure S9 ). The other four top independent GWAS signals include rs6539267, an intronic SNP within POLR3B on chromosome 12q23 (P ¼ 7.41 Â 10 À6 ; Supplementary Figure S10 ); rs13063502, a SNP that lies in a 1.7-Mb intergenic region on chromosome 3q13 (P ¼ 8.96 Â 10 À6 ; Supplementary Figure S11 ); rs7336083, located on chromosome 13q31 within a 1.9-Mb intergenic region between SLITRK6 and SLITRK1 (ref. 12) (P ¼ 9.49 Â 10 À6 ; Supplementary Figure S12); and rs769111, an intergenic SNP on chromosome 7p21 between THSD7A and TMEM106B (P ¼ 1.20 Â 10 À5 ; Supplementary  Figure S13 ). No effect-size heterogeneity was present between the three European-derived subpopulations for SNPs rs7868992, rs6539267 and rs7336083 ( Supplementary Figures S9--13 ). rs13063592 and rs769111 demonstrated moderate heterogeneity (I 2 ¼ 45.4 and 64.2%, respectively), although the direction of effect was consistent across the EU, AJ and FC populations. Supplementary  Table S5 , Supplementary Figures S9c, S14 ). Examination of an LDpruned set of top SNPs from the primary meta-analysis (412 SNPs with Po1 Â 10 À3 ) found a slight, but nonsignificant increase in the number of SNPs with the same direction of effect in the CVCR/ ANT analysis (223/412, P ¼ 0.052, one-sided binomial sign test; Supplementary Tables S2 and S3 ).
Analysis of imputed data
Imputation was performed using 1000 Genomes Project data 32 to identify additional supportive SNPs within the top signals from each meta-analysis. Q-Q plots of the primary and secondary metaanalyses incorporating imputed data demonstrated minimal inflation of the median test statistic (Supplementary Figure S15) . No imputed SNPs in either meta-analysis surpassed the genomewide significant threshold of Po5 Â 10 À8 . rs7868992 remained the top SNP overall, although its P-value dropped to 3.61 Â 10 À7 following imputation (Supplementary Figure S9c ).
Enrichment analyses of eQTLs and mQTLs
As many of the top signals in the primary meta-analysis (Po0.001) appeared to lie within or adjacent to known brain-expressed genes ( Supplementary Table S2 ), we sought functional evidence to support the observed associations by evaluating the effect of these SNPs on transcriptional expression and DNA methylation levels. We annotated all GWAS SNPs with eQTL information derived previously from LCLs, adult cerebellum and frontal cortex as well as mQTL information from adult cerebellum (Supplementary Table S2 ). The top LD-independent SNPs (412 SNPs with Po0.001) were subsequently tested for eQTL and mQTL enrichment. These top SNPs from the primary analysis were nominally enriched for eQTLs in frontal cortex (empirical P-value ¼ 0.045) with a trend toward enrichment in cerebellum (P ¼ 0.077), but no enrichment in LCLs (P ¼ 0.712; Figures 2a--c) . The highest association signals were also nominally enriched for cerebellar mQTLs (P ¼ 0.011; Figure 2d ). A similar test for SNPs located within gene loci found no enrichment (P ¼ 0.258), although missense SNPs demonstrated a borderline enrichment (P ¼ 0.098). Abbreviations: A1, reference allele; A2, alternative allele; BP, hg19 position; CHR, chromosome; eQTL, expression quantitative trait loci; LD, linkage disequilibrium; MAF, minor allele frequency; mQTL, methylation quantitative trait loci; OR, odds ratio; SNP, single-nucleotide polymorphism; TS, Tourette's syndrome. a Number of additional SNPs in LD with association P-values o1 Â 10 À3 in the primary meta-analysis (LD defined as r 2 40.5). Complete annotation of these SNPs as well as all SNPs with association P-values o1 Â 10 À3 is provided in Supplementary Table S2 . 
Examination of previously reported TS candidate genes
As an additional exploratory analysis, we examined the associations of SNPs within 50 kb of 24 previously reported candidate TS genes ( Supplementary Tables S6 and S7 ). We found no excess of lower P-values among the 2135 SNPs within these genes compared with those expected under the null, suggesting that these candidate genes are not enriched for common SNPs associated with TS ( Supplementary Figure S16) . One signal in the primary European ancestry meta-analysis had a nominal Po1 Â 10 À3 (rs10277969 within CNTNAP2, P ¼ 7.8 Â 10 À4 ), but this locus did not survive a Bonferroni correction for gene size (266 LDindependent SNPs within CNTNAP2, corrected P ¼ 0.21).
DISCUSSION
Although the current sample of 1496 TS cases and 5249 controls is the largest studied to date, no loci in our analysis reached the widely accepted statistical threshold for genome-wide significance of Pp5 Â 10 À8 (refs. 33, 34) . This observation is not surprising, given that GWA studies for other highly heritable neuropsychiatric diseases (for example, autism, bipolar disorder and schizophrenia) have required sample sizes of 5000--10 000 cases to identify definitive common risk alleles with modest effect sizes (odds ratios o1.3) (ref. 35 ). However, the marginal enrichment of functional brain variants (eQTLs and mQTLs) within the top loci in the primary meta-analysis ( Figure 2) suggests that a subset of top signals in our analysis are true associations that may contribute to TS risk through effects on gene expression and methylation. In particular, the trend toward enrichment of frontal cortex eQTLs compared with eQTLs in cerebellum and LCLs is anatomically consistent with the hypothesis that TS is caused by abnormalities in frontostriatal circuitry. 36 Nonetheless, given the nominal significance of these enrichment results, further studies in larger samples are needed before drawing definitive conclusions.
The strongest signal in the primary European ancestry metaanalysis, rs7868992, was also the top locus in the secondary metaanalysis, which incorporated an additional 496 non-European cases and controls from the CVCR and ANT Latin American population isolates (Supplementary Figure S9 ). In this combined analysis, rs7868992 initially achieved a P-value of 2.94 Â 10 À8 , surpassing the threshold for genome-wide significance. However, following imputation, this signal decreased to P ¼ 3.61 Â 10 À7 , most likely because of the incorporation of imputed data from the 148 European ancestry cases genotyped on the Illumina 370K, which does not directly interrogate rs7868992. Nonetheless, rs7868992 performed robustly on the other Illumina platforms used in this study based on review of the normalized intensity plots (Supplementary Figure S9d duplicates from the Illumina database (Supplementary Materials). Therefore, rs7868992 remains a promising candidate, but cannot be considered a TS susceptibility variant unless it is replicated in an independent sample. rs7868992 is located within an intron of COL27A1, the type XXVII collagen a chain gene. COL27A1 is a fibrillar collagen primarily expressed in cartilage, although it is expressed in the cerebellum during many stages of human development. 37, 38 Although nonfibrillar collagens have been implicated in various neurodevelopmental processes (for example, axon guidance and synaptogenesis), the function of COL27A1 in the developing nervous system is unknown. 39 The second top SNP in the primary analysis, rs6539267, is located on chromosome 12q23 within an intron of POLR3B. This gene encodes the second largest subunit of RNA polymerase III, which transcribes eukaryotic noncoding RNAs including transfer RNAs, small ribosomal RNAs and microRNAs. 40 Recessive mutations in POLR3B cause hypomyelinating leukodystrophy with a severe neurological phenotype (developmental delay, spasticity, dysarthria and ataxia), though no reported tics. 41, 42 Both the secondary meta-analysis and imputed data provide additional support for this locus, and expand the region of LD to B300 kb, including adjacent genes CKAP4, TCP11L2 and RFX4 (Supplementary Table S5 and Supplementary Figure S10 ).
The other three top loci in the primary analysis are located within large intergenic regions. rs13063502 on 3q13.1 lies between the noncoding complementary DNA FLJ25363 and PVRL3, which resides 1.5 Mb telomeric to rs13063502 and is expressed primarily in placenta and testis. 43 rs769111 on 7p21.3 is situated between THSD7A, a gene expressed almost exclusively in developing endothelial cells, 44 and TMEM106B, a gene recently associated with frontotemporal dementia with TDP-43 inclusions, whose primary function in the brain remains to be elucidated. 45 Last, rs7336083 lies in a 1.9-Mb intergenic region between SLITRK1 and SLITRK6 on chromosome 13q31. Although SLITRK1 is an a priori candidate TS susceptibility gene based on previous identification of both rare functional variants 12 and common haplotypes 46 in TS patients, functional annotation indicates that rs7336083 is a cerebellar eQTL of SLITRK6. Candidate gene analysis of all genotyped SNPs within 50 kb of SLITRK1 identified no nominally associated SNPs ( Supplementary Table S9 ), including two SNPs recently reported to be associated with TS in a separate European ancestry sample 47 (rs9593835 and rs9546538; P ¼ 0.52 and P ¼ 0.98, respectively, in this study). Of note, the association signals in rs7336083 and rs13063502 decreased in the secondary meta-analysis (Supplementary Figures S11 and S12 and Supplementary Table S3 ). It remains to be determined whether these signal reductions are indicative of false positive associations, random signal fluctuations or genetic heterogeneity between the European ancestry samples and the Latin American CVCR/ANT samples used in the secondary analysis.
This study has several potential limitations. The use of shared controls genotyped previously on different Illumina platforms creates the possibility of a systematic technical bias. To address this concern, we employed stringent, iterative individual platform QC procedures, tests of cross-platform concordance using sample duplicates and additional extensive testing for differential missing data between platforms. We also excluded SNPs known to perform differentially across Illumina platforms that can cause spurious results if not recognized (N Cox, personal communication). 48 The minimal inflation of the median test statistic in the primary meta-analysis (l GC ¼ 0.996), as well as the nominal enrichment of the top signals for SNPs with known functional significance in brain, argues that these efforts effectively mitigated this potential confound.
Second, there was residual population stratification between the TS cases from the CVCR and control samples from ANT. Although initially thought to have arisen from common founders, 22 recent studies suggest that these populations have slight differences in Native American ancestry (A Ruiz-Linares and NB Freimer, personal communication). Although the resulting l GC of 1.04 in the CVCR/ ANT subpopulation analysis is relatively small and thus is likely not to introduce significant bias in a meta-analysis, we chose to reserve these non-European samples for a secondary analysis to provide supportive evidence to individual candidate susceptibility loci. Although we did not find significant evidence for a consistent direction of effect between the top signals in the primary European ancestry meta-analysis and those in the CVCR/ANT subpopulation analysis, it is important to note that the CVCR/ANT samples are an admixed population with a significant proportion of non-European ancestry, 49 and thus do not represent a true replication sample for the European ancestry meta-analysis.
In summary, this study represents the first GWAS of TS. Despite the lack of genome-wide significant loci, the study provides an important foundation for future replication efforts and lays the groundwork for the eventual identification of definitive common TS susceptibility variants. The data also contribute to the still nascent understanding of the underlying genetic architecture of TS, which is likely to include genetic variation across the allelic frequency spectrum. 13,47,50--52 Our results also parallel those of other common neuropsychiatric disorders, for which increased sample sizes have generated significant findings for both common and rare variants that together provide key insights into previously unknown disease mechanisms. 53--55 Finally, the current data will facilitate examination of the proposed genetic relationships between TS and its common co-occurring conditions, OCD and attention-deficit hyperactivity disorder, 8 as well as those from additional psychiatric disorders, 35 with the goal of identifying the biological pathways shared by these common neurodevelopmental conditions. 
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